We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Psoriasis Patients at Increased Risk for Heart Attack

By HospiMedica staff writers
Posted on 03 Nov 2006
A new study has found that psoriasis is an independent risk factor for myocardial infarction (MI), and this risk is greatest in young patients with severe psoriasis.

Researchers from the University of Pennsylvania School of Medicine (Philadelphia, USA) conducted a perspective population-based cohort study to determine the risk of heart attack in patients with psoriasis when controlling for major cardiovascular risk factors. More...
The study data were collected from 1988-2002 by more than 500 general practitioners in the United Kingdom. The study population consisted of psoriasis patients aged 20-90, of whom 127,139 were defined as having mild psoriasis and 3,831 were defined as having severe psoriasis. Adjustments were made for hypertension, diabetes, history of heart attack, hyperlipidemia, age, sex, smoking, and body mass index (BMI). Each patient was matched to up to five control subjects who did not have psoriasis.

The study revealed that the incidence of heart attack was higher in patients with severe psoriasis (5.13 MIs per 1,000 person-years) and mild psoriasis (4.04 MIs per 1,000 person-years) compared with control patients (3.58 MIs per 1,000 person-years). Younger patients with severe psoriasis had the highest relative risk of heart attack. For example, a 40-year-old patient with severe psoriasis had more than double the risk of MI. The authors said that the magnitude of association between severe psoriasis and MI in those less than 50 years of age is similar to the magnitude of association for other major cardiac risk factors. The results of the study appear in the October 11, 2006, issue of The Journal of the American Medical Association (JAMA).

"Several hospital-based studies have indicated that psoriasis is associated with a higher prevalence of cardiovascular diseases, including MI,” said Joel M. Gelfand, M.D., M.S, an assistant professor of dermatology. "However, these studies did not control for any associated risk factors for MI.”

Psoriasis is a common, chronic immune-mediated disease that affects about 2-3% of the population. The chronic, non-contagious disease occurs when the growth of new skin cells rapidly accelerates, resulting in thick, red, scaly, inflamed patches on the skin surface. There is currently no cure for psoriasis, but many treatment options are available.



Related Links:
University of Pennsylvania School of Medicine

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.